NCT07175922 Research Into the Expression of the csgA-gene and How it Changes in Patients With Parkinson's Disease
| NCT ID | NCT07175922 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Vertero Therapeutics |
| Condition | Parkinsons Disease (PD) |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2025-09-25 |
| Primary Completion | 2026-03-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2025-09-25 with a primary completion date of 2026-03-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study seeks to understand the prevalence and variability of a gut bacteria gene called csgA in people with Parkinson's Disease. This understanding could inform development of potential new therapies targeting the gut in Parkinson's Disease.
Eligibility Criteria
Inclusion Criteria: * Between 18-80 years of age at ICF signing (inclusive) * A diagnosis of PD within 10 years from the time of ICF signing * Current or history of gastrointestinal (GI) dysfunction or constipation based on screening assessment * All participants must understand and provide written informed consent prior to any study specific procedures * Able to speak, read, and understand study procedures in Dutch sufficiently to allow completion of all study assessments Exclusion Criteria: * Any known GI disorder if deemed clinically significant by the investigator. GI disorders may include, but are not limited to: Crohn's disease, ulcerative colitis, celiac disease, irritable bowel syndrome, or lactose intolerance * Recent GI infection in the past 3 months if deemed clinically significant by the investigator. * Major GI surgery (excluding appendectomy/cholecystectomy), such as bariatric surgery, gastrectomy, esophagectomy, vagotomy, small intestine surgeries, any type of colectomy, colostomy and anorectal surgeries if deemed clinically significant by the investigator * Any known current or past eating disorder if deemed clinically significant by the investigator * Use of systemic antibiotics within 6 months prior to enrollment
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07175922 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Parkinsons Disease (PD). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07175922 currently recruiting?
Yes, NCT07175922 is actively recruiting participants. Contact the research team at clintrials@chdr.nl for enrollment information.
Where is the NCT07175922 trial being conducted?
This trial is being conducted at Leiden, Netherlands.
Who is sponsoring the NCT07175922 clinical trial?
NCT07175922 is sponsored by Vertero Therapeutics. The trial plans to enroll 200 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.